Background The Cerebrovascular Antiplatelet Trialists' Collaborative Group was formed to obtain and analyze individual patient data from the major randomized trials of common antiplatelet regimens after cerebral ischemia. Although the risk of stroke can be reduced by antiplatelet drugs, there continues to be uncertainty about the balance of risk and benefits of different antiplatelet regimens for an individual patient. Aims Our aim is to provide clinicians with a thorough evidence-based answer on these therapeutic alternatives. Methods We have identified six large randomized trials and plan to meta-analyze the data on an individual patient level. In total, these trials have enrolled 46 948 patients with cerebral ischemia. Uniquely, the Cerebrovascular Antiplatelet Trialists' Collaborative Group has secured access to the individual data of all of these trials, with the participation of key investigators and pharmaceutical companies. Our principal objective includes deriving a reliable estimate of the efficacy of different antiplatelet regimens on key outcomes including serious vascular events, major ischemic events, major bleeding, and intracranial hemorrhage.
Introduction
Stroke is a major cause of death and disability worldwide (1, 2) . Primary prevention is most important in the reduction of the burden of stroke, but adequate secondary prevention is also essential. About 30% of strokes occur in individuals with a previous transient ischemic attack (TIA) or stroke (3) . Recurrent strokes are usually more severe than first strokes and are more likely to cause dementia (4) . Strategies that are recommended as first-line treatment in secondary prevention of noncardioembolic stroke or TIA include the use of aspirin, clopidogrel, and extended-release dipyridamole plus aspirin. However, despite data supporting the use of antiplatelet agents, there continues to be considerable uncertainty regarding which antiplatelet agent to use and whether specific patient groups would benefit more from a specific regimen.
Although a number of reviews of overall trial results have been conducted (5) (6) (7) , these could only address reported outcomes and were limited statistically. Only an individual patient data (IPD) meta-analysis is able to standardize analytical techniques, inclusion criteria, and outcome definitions across studies. Moreover, an IPD meta-analysis is able to explore the effects of treatment on important safety outcomes such as major bleeding and intracranial hemorrhage and allow reliable pooled subgroup analyses. In addition, IPD enables the assessment of an individual's risk for different health and safety outcomes collected in clinical trials.
Methods

The Cerebrovascular Antiplatelet Trialists' collaborative group (CAT)
The CAT group is a collaborative effort to combine IPD from the major randomized controlled trials investigating the use of Correspondence: Jacoba P. Greving*, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Internal Mail Str 6.131, PO Box 85500, 3508 GA Utrecht, The Netherlands. E-mail: J.P.Greving@umcutrecht.nl different antiplatelet regimens in patients with cerebral ischemia. The group consists of leading investigators of these trials and international experts.
Objectives
The aims and objectives of the CAT IPD meta-analysis include • to reconstruct the aggregate data from the individual trials to ensure that the dataset is correct • to standardize inclusion definitions across trials (e.g., TIA, noncardioembolic stroke)
• to standardize outcome definitions across trials • to conduct a meta-analysis of IPD to assess the efficacy and safety of antiplatelet therapy in patients with cerebral ischemia • to develop and validate prognostic models for the risk of major ischemic events, major bleeding, and intracranial hemorrhage in patients with noncardioembolic stroke, and • to assess the effectiveness of aspirin plus dipyridamole compared with clopidogrel according to the individual's risk of major bleeding and major ischemic events
Study inclusion criteria
Studies were included if they were: (a) randomized controlled trials for long-term secondary prevention of stroke; (b) conducted in patients with cerebral ischemia; (c) randomized patients to aspirin, or to antiplatelet drugs that are recommended as first-line treatment in secondary prevention of stroke as an alternative to aspirin or in addition (aspirin plus dipyridamole, clopidogrel) (8, 9) ; and (d) published in peer-reviewed journals before December 2010. We excluded studies if daily aspirin doses outside current recommended doses (50-325 mg) for secondary stroke prevention were used and studies that examined trifusal, cilostazol, terutroban, or ticlopidine because these agents have not been recommended as first-line treatment for secondary stroke prevention. Finally, to assess the long-term efficacy and safety of these agents, only RCTs with treatment durations of at least oneyear were included.
Eligible studies
We identified six trials that met all inclusion criteria: the trial of Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) (10), the second European Stroke Prevention Study (ESPS-2) (11), Management of ATherothrombosis with Clopidogrel in High-risk patients (MATCH) trial (12) , Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial (CHARISMA) (13), the European/ Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) (14) , and the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial (15) . A standardized data request form was generated to obtain IPD for each eligible trial. Data collection was restricted to patients with cerebral ischemia (i.e. subgroups of the CAPRIE trial and CHARISMA trial).
At the time of this publication, IPD on 46 948 patients with cerebral ischemia (representing all six trials) has been received by the coordinating center, the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht. Details of the included trials are presented in Table 1 and demographic variables in Table 2 . There were 41 437 patients with a noncardioembolic ischemic stroke (defined as patients with an ischemic stroke as qualifying event and no history of atrial fibrillation), 1419 patients with likely a cardioembolic stroke, and 4087 patients with TIA as qualifying event.
Harmonization of outcome events
Detailed consideration will be given to the outcome definitions used in the original trial reports. We will accept the reported definitions of ischemic stroke, intracranial hemorrhage (including intracerebral hemorrhage, subarachnoid hemorrhage, and epidural and subdural hematomas), all-cause mortality, death from nonvascular causes, and myocardial infarction (MI) as defined by the trial investigators and will not attempt to retrospectively reclassify events. Composite outcome definitions of stroke and vascular death vary across the trials. In CAPRIE, MATCH, and CHARISMA, subdural and epidural hematomas were included as stroke outcome. For the IPD meta-analysis, subdural and epidural hematomas will be counted as intracranial hemorrhages, but not as strokes; subarachnoid and intracerebral hemorrhages will be counted in both categories. In CHARISMA, hemorrhagic transformations of ischemic stroke were included as intracranial hemorrhages. For the IPD meta-analysis, hemorrhagic transformations of ischemic stroke will be counted as ischemic strokes. In ESPS-2, MATCH, CHARISMA, ESPRIT, and PRoFESS, hemorrhagic deaths from any origin were included in the composite outcome vascular death. In CAPRIE, they were not, although they were recorded. For the IPD meta-analysis, vascular death will include hemorrhagic deaths from any origin.
Five trials reported major bleeding although the definitions varied (Supporting Information Table S1 ). CAPRIE did not report major bleeding as safety outcome in the original trial report but recorded it as adverse event (10) . In MATCH and CHARISMA, major bleeding did not include life-threatening (severe) bleeding. For the IPD meta-analysis, major bleeding will compromise life-threatening (severe) bleeding as a subset.
Primary and secondary outcomes
The primary outcome measure of efficacy will be any serious vascular event (i.e. nonfatal stroke, nonfatal MI, or death from a vascular cause, including sudden death, death from pulmonary embolism, death from any hemorrhage, and death from an unknown cause), in line with the Antithrombotic Trialists' Collaboration. The secondary outcome measure of efficacy will be all major ischemic events defined as the composite of ischemic stroke, MI, or nonhemorrhagic death from vascular causes.
The primary outcome measure of safety for this IPD metaanalysis will be major bleeding as defined by bleeding that was fatal, intracranial, or causing hemodynamic compromise that required blood or fluid replacement, inotropic support, or surgical intervention. Secondary outcome measure of safety will be primary intracranial hemorrhage.
Statistical analysis
Due to the complexity of the statistical analyses, the following section represents the planned principal analyses; some modifications and secondary analyses are likely to emerge during the project. Here, we provide the main line of our statistical analyses.
Careful initial evaluation will be performed to ensure completeness of data and to check consistency of the results of the Protocol primary analyses for each trial with published reports. Baseline characteristics of patients will be presented separately for each trial and overall. Continuous variables will be presented as mean and standard deviation (or median and range if not normally distributed). Binary and categorical variables will be presented as frequencies and percentages.
IPD meta-analysis
All efficacy and safety analyses will be performed according to the intention-to-treat principle and involve a time-to-event approach. We will calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for each outcome and trial separately, and we will check these findings against published data for accuracy. We will estimate pooled HRs and corresponding 95% CIs with a random effects two-stage model (16) . We will assess the appropriateness of pooling of data across trials with use of the Cochran Q statistic and I 2 test for heterogeneity (17) . Each of these analyses will be performed unadjusted as well as adjusted for key baseline variables and in key subgroups according to treatment allocation, qualifying diagnosis (TIA vs. noncardioembolic ischemic stroke), timing of the included trials (more recent trials vs. older trials), and timing of initiation of therapy since the qualifying stroke or TIA.
Prognostic models
We will develop and validate prognostic models for the risk of three outcome events: vascular events, major bleeding, and intracranial hemorrhage. The selection of potential predictors will be based on the literature as well as the availability of information in the trials. The building of the prediction models will start with univariable assessment of all possible predictors with the predefined outcomes. Multivariable Cox regression analysis will be performed, and the best predictive model will be developed (18, 19) . In all analyses, continuous variables will be kept continuous, and the nature of their relation to outcome evaluated with fractional polynomials. The performance of the prognostic models will be evaluated by discrimination and calibration. The discriminative performance (i.e. the extent to which the prognostic models enable discrimination between patients with and without outcome) will be described by the concordance (or c) statistic (or area under the receiver operating characteristic curve) and its 95% CI. Internal validation of the model will be determined by a bootstrapping procedure with 200 replications. In each replication, a random sample from the original dataset will be drawn with replacement. We will multiply the regression coefficients by the shrinkage factor derived from the bootstrapping procedures to quantify the amount of optimism and to correct for over-fitting if necessary (19) . Calibration of the prediction models (i.e. the agreement between observed and predicted risks) will be assessed by the Gronnesby and Borgan test and graphically with a calibration plot (20) . Finally, predictors for major bleeding, intracranial hemorrhage, and major vascular events will be implemented into practically applicable risk prediction scores that enable clinicians to estimate an individuals' risk of major bleeding, intracranial hemorrhage, or major vascular events in ischemic stroke patients.
Decision analysis
In order to determine whether the developed risk prediction scores improve the decision-making process, we propose to apply decision curve analysis (21) . We will also investigate possible extensions of this method in order to incorporate benefits and risks separately. Subsequently, we will develop a Markov model to assess the incremental treatment effect of the different antithrombotic therapies in order to choose the optimal antiplatelet regimen for groups of patients with certain profiles of key risk variables. We will employ methods we used previously in other decision analyses (22, 23) . As a first step, all relevant health states, model assumptions, utilities (quality of life), and transition probabilities have to be defined. The different health states and branches of the model will be carefully discussed with stroke physicians and experts in health technology assessment. Important information to be included in the Markov model pertains to the individualized risk estimates of major bleeding, intracranial hemorrhage, and major vascular events. We will use the developed prediction models to incorporate this information into the model. Continuous risk scores will be classified into three categories (low, intermediate, and high risk) based on the observed rates of vascular events and bleedings. For each risk profile, the optimal antiplatelet regimen will be determined by means of a separate Markov decision model; the structure of the model, however, will be the same for the different risk profiles. Furthermore, sensitivity analyses of all critical variables in the Markov model will be done to evaluate their influence on the stability of the treatment recommendations. Probabilistic sensitivity analyses with Monte Carlo simulation will be used as another tool to assess uncertainty.
Discussion
This IPD meta-analysis will provide a comprehensive assessment of the role of different antiplatelet regimens in secondary prevention after noncardioembolic stroke. The Cerebrovascular Antiplatelet Trialists' Collaborative Group aims to reduce the burden of morbidity and mortality in stroke patients and provide clinicians with clear guidance on which patients will benefit from specific antiplatelet regimens.
